Immune Pharmaceuticals Inc (NASDAQ:IMNP) is a micro-cap making a name for itself as an immuno-oncology leader. There’s growing investor anticipation about the products in the drug pipeline of Immune Pharmaceuticals Inc. NASDAQ:IMNP), which is set to unveil a major immuno-oncology R&D update in New York on December 8. That could be good news for investors, who have had little to cheer about this year for IMNP. As of December, shares of the company were down 61.70 percent year-to-date. A mini-rally over the past few days has helped, but that looks like it was mostly a bounce off a 52-week low hit on December 1.
Shares of Immune Pharmaceuticals are currently trading at $3.48, giving the company a market capitalization of $45.13M. Over the most recent 52-week period, shares of the company have traded as low as $2.14 and as high as $12..80. In short, shares of the company haven’t traded above a buck in more than a year. The current trading range for IMNP is $3.35 – $3.67.
Immune Pharmaceuticals Inc (NASDAQ:IMNP) is a clinical stage biopharmaceutical company involved in the development and commercialization of targeted therapeutics in the fields of immuno-inflammation and immuno-oncology. It’s important to understand the drug pipeline for the company, which is based primarily around these two segments.
Find out when $IMNP stock reaches critical levels. Subscribe to FR Right Now by entering your Email in the box below.
The first set of products is based around immuno-inflammation. Bertilimumab is currently in Phase II clinical trials for the treatment of Bullous Pemphigoid, IBD (Ulcerative Colitis) and Atopic Dermatitis/Psoriasis. The drug is also in the preclinical stage for the treatment of NASH, a nonalcoholic fatty liver disease.
The second set of products is based around immuno-oncology. The key product here is Ceplene, which has already been approved in the EU. In addition, the company has Crolibulin/Azixa, which is in Phase II clinical trial and Nanomabs, which is in preclinical testing. Nanomabs is used for the targeted delivery of chemotherapeutics into cancer cells.
Finally, the company has one drug for the nano-dermatology market, known as Nanocyclo, which is still in preclinical testing. And it has AmiKet, which is in Phase III testing for neuropathic pain. AmiKet is being developed by the company’s pain and neurology subsidiary, Maxim Pharmaceuticals.
The name to keep an eye on here is Ceplene.
So, for investors, it’s critical to keep an eye on how these drugs are moving through the drug pipeline. Ceplene is most intriguing, because it already has EU approval, so approval from the U.S. FDA is the next obvious goal. Bertilimumab sounds intriguing, mostly because of the various uses it might have, but it’s still in Phase II trials.
So what do investors think about all this? The current consensus stock target for the stock is $2.00, based on three analyst recommendations. That represents quite a bit of upside for the stock, given the current trading price of $0.20.
But technical sentiment on the stock is mixed at best. On December 5, analysts noted a “falling wedge” pattern for IMNP. This technical trading pattern is usually a negative indicator for a bullish breakout, so there may be a battle up ahead between fundamental investors and technical investors for the future direction of IMNP. If the news released on December 8 is better than expected, then IMNP could be headed for a steep ride upwards. For more details on Immune Pharmaceuticals and other fast-moving penny stocks, please subscribe to FinanceRegistrar.com now.